Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products.
+ 1 more risk
High growth potential and slightly overvalued.
Share Price & News
How has Eton Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ETON's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: ETON underperformed the US Market which returned -14.9% over the past year.
Price Volatility Vs. Market
How volatile is Eton Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StDoes Eton Pharmaceuticals (NASDAQ:ETON) Have A Healthy Balance Sheet?
1 month ago | Simply Wall StCan We See Significant Insider Ownership On The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Share Register?
2 months ago | Simply Wall StWe're Keeping An Eye On Eton Pharmaceuticals's (NASDAQ:ETON) Cash Burn Rate
Is Eton Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ETON ($3.7) is trading below our estimate of fair value ($37.71)
Significantly Below Fair Value: ETON is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ETON is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: ETON is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ETON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ETON is overvalued based on its PB Ratio (6.3x) compared to the US Pharmaceuticals industry average (2.4x).
How is Eton Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ETON is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ETON is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ETON's is expected to become profitable in the next 3 years.
Revenue vs Market: ETON's revenue (54.9% per year) is forecast to grow faster than the US market (7.1% per year).
High Growth Revenue: ETON's revenue (54.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ETON's Return on Equity is forecast to be high in 3 years time
How has Eton Pharmaceuticals performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ETON is currently unprofitable.
Growing Profit Margin: ETON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ETON's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ETON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ETON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: ETON has a negative Return on Equity (-173.65%), as it is currently unprofitable.
How is Eton Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ETON's short term assets ($15.0M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: ETON's short term assets ($15.0M) exceed its long term liabilities ($4.6M).
Debt to Equity History and Analysis
Debt Level: ETON's debt to equity ratio (43%) is considered high.
Reducing Debt: Insufficient data to determine if ETON's debt to equity ratio has reduced over the past 5 years.
Inventory Level: ETON has a low level of unsold assets or inventory.
Debt Coverage by Assets: ETON's debt is covered by short term assets (assets are 3.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ETON has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ETON has less than a year of cash runway if free cash flow continues to reduce at historical rates of -49.9% each year
What is Eton Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ETON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ETON's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ETON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ETON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ETON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Sean Brynjelsen (47yo)
Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P ...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD493.02K) is about average for companies of similar size in the US market ($USD609.32K).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
|Independent Director||2.58yrs||US$125.00k||0.34% $224.9k|
|Independent Director||2.83yrs||US$125.00k||0.40% $266.1k|
Experienced Board: ETON's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 176.7%.
Eton Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Eton Pharmaceuticals, Inc.
- Ticker: ETON
- Exchange: NasdaqGM
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$66.165m
- Shares outstanding: 17.88m
- Website: https://www.etonpharma.com
Number of Employees
- Eton Pharmaceuticals, Inc.
- 21925 West Field Parkway
- Suite 235
- Deer Park
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ETON||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 2018|
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen, a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101 and ET-104, which are oral liquid product candidates for neurological indications; DS-300 and DS-100, which are injectable product candidates; and ET-105, a lamotrigine for oral suspension. Eton Pharmaceuticals, Inc. was founded in 2017 and is based in Deer Park, Illinois.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/03 04:29|
|End of Day Share Price||2020/04/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.